Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: Results from a population-based study

Journal of Developmental and Behavioral Pediatrics

Volumn 35, Issue 7, 2014, Pages 448-457

  Barbaresi, William J ^a   Katusic, Slavica K ^b   Colligan, Robert C ^b   Weaver, Amy L ^a   Leibson, Cynthia L ^b   Jacobsen, Steven J ^b  

^a Mayo Clinic College of Medicine   (United States)

^b Department of Health Sciences Research Division of Clinical Epidemiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DEXTROAMPHETAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHYLPHENIDATE; MINNESOTA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906887106     PISSN: 0196206X     EISSN: 15367312     Source Type: Journal    
DOI: 10.1097/DBP.0000000000000099     Document Type: Review

References (42)

1. Wigal T, Swanson JM, Regino R, et al. Stimulant medications for the treatment of ADHD; efficacy and limitations. MRDD Res Rev. 1999; 5:215-224.
2. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attentiondeficit/ hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
3. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S-49S.
4. Jensen PS. Attention Deficit Hyperactivity Disorder, State of the Science, Best Practices. Kingston, NJ: Civic Research Institute; 2002.
5. Barkley RA. Attention-Deficit Hyperactivity Disorder, A Handbook for Diagnosis and Treatment. New York/London: Guilford Press; 1998.
6. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:85S-121S.
7. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75:711-721.
8. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
9. The MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762-769.
10. National Institutes of Health Consensus Development Conference Statement. Diagnosis and treatment of attentiondeficit/ hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2000;39:182-193.
11. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attentiondeficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153:1257-1263.
12. Jensen PS, Keffle L, Roper MT, et al. Are stimulants over prescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry. 1999;38:797-804.
13. Swanson J, Lerner M, Williams L. More frequent diagnosis of attention deficit/hyperactivity disorder. N Engl J Med. 2000;333: 944.
14. Vitello B, Jensen P. Medication development and testing in children and adolescents. Arch Gen Psychiatry. 1997;54:871-876.
15. Safer D, Zito J, Fine E. Increased methylphenidate usage for attention deficit hyporeactivity disorder in the 1990s. Pediatrics. 1996;98:1084-1088.
16. LeFever G, Sawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999;89:1359-1364.
17. Angold A, Erkanli A, Egger H, Costello J. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:975-983.
18. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
19. Safer DF, Malever M. Stimulant treatment in Maryland public schools. Pediatrics. 2000;106:533-539.
20. Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends. Arch Pediatr Adolesc Med. 2001;155:560-565.
21. Hoagwood K, Kelleher KJ, Feil M, Comer DM. Treatment services for children with ADHD: a national perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:198-206.
22. Guevara S, Lozano P, Wickizer T, Mell L, Gephart H. Psychotropic medication use in a population of children who have attentiondeficit/ hyperactivity disorder. Pediatrics. 2002;109:733-739.
23. Barbaresi WJ, Katusic SK, et al. How common is attentiondeficit/ hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minnesota. Arch Pediatr Adolesc Med. 2002;217-224.
24. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust. 2002;177:21-25.
25. Romano E, Baillargeon RH, Wu HX, Robaey P, Tremblay RE. Prevalence of methylphenidate use and change over a two-year period: a nationwide study of 2-to 11-year-old Canadian children. J Pediatr. 2002;141:71-75.
26. Robison LM, Skaer TL, Sclar DA, Galin RS. Is attention deficit hyperactivity disorder increasing among girls in the US: Trends in diagnosis and the prescribing of stimulants. CNS Drugs. 2002;16: 129-137.
27. Hogarty GE, Schooler NR, Baker RW. Efficacy versus effectiveness. Psychiatr Serv. 1997;48:1107.
28. Pearson TA, Feinberg W. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. Ann Behav Med. 1997; 19:230-238.
29. Fedson DS. Measuring protection: efficacy versus effectiveness. Dev Biol Standard. 1998;95:195-201.
30. Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis. 1999;58:182S-185S.
31. Barbaresi W, Katusic SK, Colligan RC, et al. How common is attention-deficit/hyperactivity disorder? Toward resolution of the controversy: results from a population-based study. Acta Paediatr. 2004;93:55S-59S.
32. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Utilization and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA. 2001;285:60-66.
33. Katusic SK, Barbaresi W, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Case definition in epidemiologic studies of attentiondeficit/hyperactivity disorder. Ann Epidemiol. 2005;15:43-437.
34. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
35. Katusic SK, Colligan RC, Barbaresi WJ, Schaid DJ, Jacobsen SJ. Potential influence of migration bias in birth cohort studies. Mayo Clin Proc. 1998;73:1053-1062.
36. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health. US Department of Health Education and Welfare PUB (ADM); 1976: 76-338.
37. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319-324.
38. Carlson CL, Shin M, Booth J. The case for DSM-IV subtypes in ADHD. MRDD Res Rev. 1999;5:199-206.
39. Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. MRDD Res Rev.1999;5: 243-250.
40. Barkley R, McMurray M, Edelbrock C, Robbins K. Side effects of PMH in children with attention deficit hyperactivity disorder: a systematic placebo-controlled evaluation. Pediatrics. 1990;86: 184-192.
41. The treatment of attention-deficit/hyperactivity disorder. Summary, evidence report/technology assessment: Number 11. AHCPR Publication No. 99-E017, December 1999. Agency for Health Care Policy and Research. Rockville, MD.
42. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Atten Disord. 2000;3:200-211.